NCT05833893: Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
- State
- Under way
- Phase
- Phase 2
- People
- 10 planned
- Started
- 1 May 2023
- Primary completion
- 31 Dec 2025
- Arms
- Treatment group
- Results
- None posted
- 27 Apr 2023: Trial registered